The partnership marks a shift from retrospective fitness tracking toward real-time clinical diagnostics, as AI signal processing transforms single-lead wearables into medical-grade monitoring devices without the bulk of hospital equipment.
NeuralCloud Solutions, a subsidiary of AI/ML Innovations, has entered a pilot agreement with Movesense to deploy AI-powered electrocardiogram (ECG) and Holter reporting software in third-party healthcare settings.
The pilot puts NeuralCloud’s MaxYield signal processing platform and CardioYield visualization software downstream from Movesense’s medically certified wearable sensors. The goal is to boost ECG review capacity and standardize reporting in outpatient and ambulatory care—without piling more work onto clinicians.
From tracking to diagnosing
This partnership represents a notable shift in wearable technology. What started as fitness trackers counting steps has grown into something more sophisticated: devices that can spot potential heart problems in real time. The American College of Sports Medicine’s 2026 survey shows wearables are trending again—but this time it’s not about step goals. People want devices that monitor heart rhythm, blood pressure, and glucose levels.
Traditional fitness trackers tell you what happened yesterday. This pilot uses AI models trained to spot the difference between a healthy athlete’s heart and a dangerous arrhythmia. By turning lightweight wearables into continuous Holter-style monitors, the technology could enable round-the-clock cardiac monitoring during training—no bulky hospital gear required.
How bundled solutions could put medical wearables in sports shops
The partnership shows a pattern we’re seeing more often in sports tech: one company makes the sensors, another handles the AI. This setup could make it easier for sporting goods retailers to sell devices bundled with ongoing medical monitoring services.
As wearables hit medical-grade accuracy, they edge closer to insurance reimbursement territory. Health providers might start subsidizing “smart” sporting goods for cardiac rehab patients and older adults—two groups that dominated 2026 fitness trends.
The technology addresses a real concern for serious athletes and health-conscious individuals: preventing sudden cardiac death during intense exercise. AI pattern recognition can catch dangerous arrhythmias that standard ECG readings often miss in athletes, whose heart adaptations can look a lot like pathology.
When gyms become monitoring environments
The pilot echoes broader shifts we have been observing at Sporting Goods Intelligence Europe: the gym becoming a continuous monitoring environment rather than just a physical space. The pitch evolves from “this gear helps you train” to “this ecosystem makes sure you’re medically cleared to train.”
That transition pushes sporting goods companies into tougher regulatory waters. Medical device classification means GDPR and HIPAA compliance—moving the sector closer to healthcare than fashion.
The pilot is being tested with a healthcare organization and several clinic sites—names aren’t public yet. The team will focus on three things: making sure the technology actually works, checking that reports are accurate, and seeing how well it fits into doctors’ daily routines. Whether this goes to market depends on getting the right contracts signed, passing regulatory reviews, and proving the pilot works as promised.
About the Companies
Movesense is a Finland-based wearable sensor technology company specializing in ECG, heart rate variability (HRV), and motion sensing for medical, sports, and research applications. The company holds ISO13485:2016 certification as a medical device manufacturer and develops programmable sensors that integrate into custom digital health solutions. Movesense devices support single-lead ECG acquisition in chest-strap and body-worn configurations, available in both medical and non-medical variants.
AI/ML Innovations is a technology company focused on artificial intelligence and neural networks for digital health applications. Its platforms use signal processing and deep learning to convert biometric data into clinical insights. AIML shares trade on the Canadian Securities Exchange (CSE:AIML), OTCQB Venture Market (AIMLF), and Frankfurt Stock Exchange (42FB). NeuralCloud Solutions operates as AIML’s subsidiary, developing MaxYield ECG signal processing and CardioYield visualization software.